Clinical Research Directory

Inclusion Criteria: * Subjects with MM (Multiple Myeloma) * Partial response, stable disease or progression after induction therapy (including ASCT) * Measurable disease * Successful peripheral blood stem cell collection with G-CSF * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 * Signed informed consent * Patients after first-line induction therapy Exclusion Criteria: * Another malignancy requiring treatment at the time of inclusion * History of interstitial lung disease or pneumonitis * Patients with any other known concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes; cardiovascular disease including congestive heart failure NYHA Class III or IV, myocardial infarction within 6 months, and poorly controlled hypertension) which, in the opinion of the investigator could compromise participation in the study * Uncontrolled bacterial or fungal infection at the time of enrollment * Pregnancy * Somatic or psychiatric disorder making the patient unable to sign informed consent * Active or prior documented autoimmune disease requiring systemic treatment * Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA4 therapy